Vivos Therapeutics, Inc.
Business
Vivos Therapeutics develops and distributes proprietary oral appliances for obstructive sleep apnea treatment, including FDA-cleared DNA, mRNA, and mmRNA devices. The company operates through two channels: training independent dentists as Vivos Integrated Providers, and acquiring sleep medical practices to provide diagnostic and treatment services. Vivos also offers complementary diagnostic tools, home sleep testing, practice management software, and clinical training. The company operates primarily in the United States.
Summary from 10-K filed 2026-04-15
Financials
Consolidated Statement of Income
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Total revenue | 17 | 15 | 14 | 16 | 17 | |
| Cost of sales (exclusive of depreciation and amortization shown separately below) | 7 | 6 | 6 | 6 | 4 | |
| Gross profit | 11 | 9 | 8 | 10 | 13 | |
| General and administrative | 28 | 18 | 22 | 29 | 26 | |
| Sales and marketing | 1 | 2 | 2 | 5 | 6 | |
| Depreciation and amortization | 1 | 581,000 | 621,000 | 669,000 | 733,000 | |
| Total operating expenses | 30 | 20 | 26 | 35 | 33 | |
| Operating loss | −20 | −11 | −17 | −25 | −20 | |
| Other expense | −1 | −110,000 | −212,000 | −190,000 | −9,000 | |
| Other income | 145,000 | 145,000 | 147,000 | 89,000 | — | |
| Loss before income taxes | −21 | −11 | −14 | −24 | −20 | |
| Net loss | −21 | −11 | — | — | — | |
| Net loss attributable to non-controlling interest | −60,000 | — | — | — | — | |
| Net loss attributable to stockholders | −21 | −11 | −14 | −24 | −20 | |
| Net loss per share (basic) | −2.07 | −2.22 | −11.14 | −25.9 | −0.96 | |
| Net loss per share (diluted) | −2.07 | −2.22 | −11.14 | −25.9 | — | |
| Weighted average number of shares of Common Stock outstanding (basic) | 10 | 5 | 1 | 920,592 | 21,233 | |
| Weighted average number of shares of Common Stock outstanding (diluted) | 10 | 5 | 1 | 920,592 | — |
Consolidated Balance Sheet
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 2 | 6 | 2 | 4 | 24 | |
| Accounts receivable, net of allowance of $882 and $390, respectively | 2 | 430,000 | 202,000 | 457,000 | 1 | |
| Prepaid expenses and other current assets | 774,000 | 783,000 | 616,000 | 1 | 2 | |
| Total current assets | 4 | 7 | 2 | 5 | 27 | |
| Goodwill | 9 | 3 | 3 | 3 | 3 | |
| Property and equipment, net | 4 | 3 | 3 | 3 | 3 | |
| Operating lease right-of-use asset | 4 | 1 | 1 | 2 | — | |
| Intangible assets, net | 4 | 409,000 | 420,000 | 302,000 | 341,000 | |
| Deposits and other | 228,000 | 216,000 | 307,000 | 374,000 | 356,000 | |
| Total assets | 25 | 15 | 11 | 14 | 34 | |
| Accounts payable | 2 | 1 | 2 | 1 | 920,000 | |
| Accrued expenses | 6 | 2 | 2 | 2 | 3 | |
| Current portion of contract liabilities | 479,000 | 896,000 | 2 | 3 | 2 | |
| Current portion of operating lease liability | 672,000 | 477,000 | 474,000 | 419,000 | — | |
| Current portion of financing lease liability | 55,000 | — | — | — | — | |
| Current portion of debt | 8 | — | — | — | 1 | |
| Other current liabilities | 850,000 | 273,000 | 198,000 | 145,000 | — | |
| Total current liabilities | 18 | 5 | 7 | 7 | 8 | |
| Contract liabilities, net of current portion | — | 97,000 | 289,000 | 112,000 | — | |
| Employee retention credit liability | 3 | 1 | 1 | — | — | |
| Operating lease liability, net of current portion | 4 | 1 | 2 | 2 | — | |
| Financing lease liability, net of current portion | 113,000 | — | — | — | — | |
| Debt, net of current portion | 469,000 | — | — | — | — | |
| Other liabilities | 1 | — | — | — | — | |
| Total liabilities | 27 | 7 | 10 | 9 | 8 | |
| Commitments and contingencies (Note 14) | — | — | — | — | — | |
| Preferred Stock, $0.0001 par value per share. Authorized 50,000,000 shares; no shares issued and outstanding | — | — | — | — | — | |
| Common Stock, $0.0001 par value per share. Authorized 200,000,000 shares; issued and outstanding 9,286,609 shares as of December 31, 2025 and 5,889,520 shares as December 31, 2024 | 1,000 | — | — | — | 2,000 | |
| Additional paid-in capital | 124 | 112 | 93 | 84 | 81 | |
| Accumulated deficit | −125 | −104 | −93 | −79 | −56 | |
| Total stockholders equity/(deficit) | −1 | 8 | 411,000 | 5 | 26 | |
| Non-controlling interest | 60,000 | — | — | — | — | |
| Total equity/(deficit) | −2 | 8 | 411,000 | — | — | |
| Total liabilities and equity/(deficit) | 25 | 15 | 11 | 14 | 34 |
Consolidated Statement of Cash Flows
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Stock-based compensation expense | 661,000 | 762,000 | 1 | 2 | 3 | |
| Depreciation and amortization | 1 | 581,000 | 621,000 | 669,000 | 733,000 | |
| Fair value of common stock issued for services | — | 11,000 | 87,000 | — | 20,000 | |
| Fair value of warrants issued for services | — | 31,000 | 737,000 | 711,000 | 232,000 | |
| Accounts receivable, | −217,000 | −228,000 | 255,000 | 746,000 | 228,000 | |
| Operating lease liabilities, net | 55,000 | −129,000 | −109,000 | 7,000 | 548,000 | |
| Prepaid expenses and other current assets | 19,000 | −167,000 | 832,000 | 126,000 | −902,000 | |
| Deposits | 29,000 | 105,000 | 80,000 | −16,000 | −47,000 | |
| Accounts payable | 524,000 | −1 | 734,000 | 491,000 | 139,000 | |
| Accrued expenses | 4 | −39,000 | 422,000 | −941,000 | 1 | |
| Other liabilities | 483,000 | — | 41,000 | 144,000 | — | |
| Contract liability | −514,000 | −1 | −611,000 | 638,000 | −539,000 | |
| Net cash used in operating activities | −15 | −13 | −12 | −20 | −16 | |
| Acquisitions of property and equipment | −2 | −568,000 | −803,000 | −924,000 | −2 | |
| Cash paid for acquisition of SCN | −5 | — | −50,000 | — | — | |
| Net cash used in investing activities | −8 | −568,000 | −853,000 | −924,000 | −3 | |
| Proceeds from issuance of common stock | 6 | 8 | 4 | — | 28 | |
| Proceeds from issuance of debt | 11 | — | — | — | — | |
| Proceeds from issuance of warrants | 2 | 8 | — | — | — | |
| Proceeds from issuance of pre-funded warrants | 609,000 | 4 | 8 | — | — | |
| Proceeds from exercise of warrants | 866,000 | — | — | — | — | |
| Payments for issuance costs | −837,000 | −1 | −1 | — | −2 | |
| Reduction of finance lease liability | −28,000 | — | — | — | — | |
| Net cash provided by financing activities | 19 | 18 | 11 | — | 24 | |
| Net increase (decrease) in cash and cash equivalents | −4 | 5 | −2 | −21 | 6 | |
| Cash paid for interest | — | 9,000 | — | — | 18,000 | |
| Conversion of promissory note, net of issuance costs | 1 | — | — | — | — | |
| Common stock issued as consideration for acquisition | 1 | — | — | — | — | |
| Contingent consideration as consideration for acquisition of SCN, net of valuation adjustment | 1 | — | — | — | — | |
| Fair value of warrants issued in private placement | — | 262,000 | — | — | — | |
| Acquisitions of property and equipment by issuing debt | 922,000 | — | — | — | — | |
| Conversion of debt to equity | 25,000 | — | — | — | — |
Filings
Material Events
Insiders
Institutional Holders
Frequently asked questions
What is Vivos Therapeutics, Inc.'s CIK number?
Vivos Therapeutics, Inc.'s SEC CIK number is 0001716166 (1716166). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find Vivos Therapeutics, Inc.'s SEC filings?
All of Vivos Therapeutics, Inc.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.
When did Vivos Therapeutics, Inc. last report earnings?
Vivos Therapeutics, Inc. (VVOS) most recently filed an earnings 8-K with the SEC on Apr 15, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001493152-26-016865). This is Vivos Therapeutics, Inc.'s most recent earnings filing of record — not a forecast of its next earnings date.
What is Vivos Therapeutics, Inc.'s most recent earnings 8-K?
Vivos Therapeutics, Inc.'s latest earnings 8-K (Item 2.02) was filed Apr 15, 2026 under accession 0001493152-26-016865. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.
View Vivos Therapeutics, Inc.'s latest earnings 8-K →
Look up any company's CIK number →